Top

Published in:

01-04-2018 | Research Article

Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls

Authors: R. de Cássia Viu Carrara, A. M. Fontes, K. J. Abraham, M. D. Orellana, S. K. Haddad, P. V. B. Palma, R. A. Panepucci, M. A. Zago, D. T. Covas

Published in: Clinical and Translational Oncology | Issue 4/2018

Abstract

Purpose

The fusion gene BCR-ABL has an important role to the progression of chronic myeloid leukemia (CML) and several signaling pathways have been characterized as responsible for the terminal blastic phase (BP). However, the initial phase, the chronic phase (CP), is long lasting and there is much yet to be understood about the critical role of BCR-ABL in this phase. This study aims to evaluate transcriptional deregulation in CD34+ hematopoietic cells (CD34+ cells) from patients with untreated newly diagnosed CML compared with CD34+HC from healthy controls.

Methods

Gene expression profiling in CML-CD34 cells and CD34 cells from healthy controls were used for this purpose with emphasis on five main pathways important for enhanced proliferation/survival, enhanced self-renewal and block of myeloid differentiation.

Results

We found 835 genes with changed expression levels (fold change ≥ ±2) in CML-CD34 cells compared with CD34 cells. These include genes belonging to PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways. Four of these pathways converge to MYC activation. We also identified five transcripts upregulated in CD34-CML patients named OSBPL9, MEK2, p90RSK, TCF4 and FZD7 that can be potential biomarkers in CD34-CML-CP.

Conclusion

We show several mRNAs up- or downregulated in CD34-CML during the chronic phase.

Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441–53. doi:10.1038/nrc2147.CrossRefPubMed

Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010–22. doi:10.1182/blood-2003-12-4111.CrossRefPubMed

Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene. 2003;22(25):3952–63. doi:10.1038/sj.onc.1206620.CrossRefPubMed

Kronenwett R, Butterweck U, Steidl U, Kliszewski S, Neumann F, Bork S, et al. Distinct molecular phenotype of malignant CD34+ hematopoietic stem and progenitor cells in chronic myelogenous leukemia. Oncogene. 2005;24(34):5313–24. doi:10.1038/sj.onc.1208596.CrossRefPubMed

Diaz-Blanco E, Bruns I, Neumann F, Fischer JC, Graef T, Rosskopf M, et al. Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia. 2007;21(3):494–504. doi:10.1038/sj.leu.2404549.CrossRefPubMed

Machova Polakova K, Kulvait V, Benesova A, Linhartova J, Klamova H, Jaruskova M, et al. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. J Cancer Res Clin Oncol. 2015;141(5):887–99. doi:10.1007/s00432-014-1845-6.CrossRefPubMed

Heller G, Topakian T, Altenberger C, Cerny-Reiterer S, Herndlhofer S, Ziegler B, et al. Next-generation sequencing identifies major DNA methylation changes during progression of Ph⁺ chronic myeloid leukemia. Leukemia. 2016;30(9):1861–8. doi:10.1038/leu.2016.143.CrossRefPubMedPubMedCentral

Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445–64. doi:10.1038/nrclinonc.2015.61.CrossRefPubMedPubMedCentral

Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R, et al. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia. 2007;21(5):949–55. doi:10.1038/sj.leu.2404657.CrossRefPubMed

10.

Yeh CH, Moles R, Nicot C. Clinical significance of microRNAs in chronic and acute human leukemia. Mol Cancer. 2016;15(1):37. doi:10.1186/s12943-016-0518-2.CrossRefPubMedPubMedCentral

11.

Yong AS, Melo JV. The impact of gene profiling in chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22(2):181–90. doi:10.1016/j.beha.2009.04.002.CrossRefPubMed

12.

Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109(10):4399–405. doi:10.1182/blood-2006-09-045104.CrossRefPubMed

13.

van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C, Schellings MW, et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell. 2011;10(5):769–79. doi:10.1111/j.1474-9726.2011.00714.x.CrossRefPubMedPubMedCentral

14.

Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38(9):1060–5. doi:10.1038/ng1855.CrossRefPubMedPubMedCentral

15.

Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63(4):789–99.PubMed

16.

Tognon R, Gasparotto EP, Leroy JM, Oliveira GL, Neves RP, Carrara Rde C, et al. Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. J Clin Pathol. 2011;64(1):75–82. doi:10.1136/jcp.2010.080895.CrossRefPubMed

17.

Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98(9):5116–21. doi:10.1073/pnas.091062498.CrossRefPubMedPubMedCentral

18.

Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45.CrossRefPubMedPubMedCentral

19.

Skoda J, Hermanova M, Loja T, Nemec P, Neradil J, Karasek P, et al. Co-expression of cancer stem cell markers corresponds to a pro-tumorigenic expression profile in pancreatic adenocarcinoma. Plos one. 2016;11(7):e0159255. doi:10.1371/journal.pone.0159255.CrossRefPubMedPubMedCentral

20.

Cheng J, Liu C, Liu L, Chen X, Shan J, Shen J, et al. MEK1 signaling promotes self-renewal and tumorigenicity of liver cancer stem cells via maintaining SIRT1 protein stabilization. Oncotarget. 2016;7(15):20597–611. doi:10.18632/oncotarget.7972.PubMedPubMedCentral

21.

Gargini R, Cerliani JP, Escoll M, Anton IM, Wandosell F. Cancer stem cell-like phenotype and survival are coordinately regulated by Akt/FoxO/Bim pathway. Stem Cells. 2015;33(3):646–60. doi:10.1002/stem.1904.CrossRefPubMed

22.

Hill R, Wu H. PTEN, stem cells, and cancer stem cells. J Biol Chem. 2009;284(18):11755–9. doi:10.1074/jbc.R800071200.CrossRefPubMedPubMedCentral

23.

Lombardo Y, Scopelliti A, Cammareri P, Todaro M, Iovino F, Ricci-Vitiani L, et al. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology. 2011;140(1):297–309. doi:10.1053/j.gastro.2010.10.005.CrossRefPubMed

24.

Sette G, Fecchi K, Salvati V, Lotti F, Pilozzi E, Duranti E, et al. Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res. 2013;32:91. doi:10.1186/1756-9966-32-91.CrossRefPubMedPubMedCentral

25.

Ciuffreda L, Falcone I, Incani UC, Del Curatolo A, Conciatori F, Matteoni S, et al. PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv Biol Regul. 2014;56:66–80. doi:10.1016/j.jbior.2014.07.002.CrossRefPubMed

26.

Zhao Y, Zhang W, Guo Z, Ma F, Wu Y, Bai Y, et al. Inhibition of the transcription factor sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts. Oncol Rep. 2013;30(4):1782–92. doi:10.3892/or.2013.2627.CrossRefPubMed

27.

Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011;11:71. doi:10.1186/1471-230X-11-71.CrossRefPubMedPubMedCentral

28.

Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35. doi:10.1016/j.cell.2012.03.003.CrossRefPubMedPubMedCentral

29.

Fallah P, Amirizadeh N, Poopak B, Toogeh G, Arefian E, Kohram F, et al. Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Int J Lab Hematol. 2015;37(4):560–8. doi:10.1111/ijlh.12351.CrossRefPubMed

30.

Chang CC, Hsu WH, Wang CC, Chou CH, Kuo MY, Lin BR, et al. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res. 2013;73(13):4147–57. doi:10.1158/0008-5472.CAN-12-4085.CrossRefPubMed

Title: Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls
Authors: R. de Cássia Viu Carrara
A. M. Fontes
K. J. Abraham
M. D. Orellana
S. K. Haddad
P. V. B. Palma
R. A. Panepucci
M. A. Zago
D. T. Covas
Publication date: 01-04-2018
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 4/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1751-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2018

Correction to: High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells

Validation of the AJCC 8th lung cancer staging system among patients with small cell lung cancer

High expression of HO-1 predicts poor prognosis of ovarian cancer patients and promotes proliferation and aggressiveness of ovarian cancer cells

Treatment of childhood astrocytomas with irinotecan and cisplatin

Analysis of blood markers for early breast cancer diagnosis

Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine

Keynote webinar | Spotlight on antibody–drug conjugates in cancer